Degraders, ADCs, PDCs Shine In Latest China Funding Rounds

 
• By Dexter Jie Yan

Degron and TargetRx’s targeted protein degrader programs helped the firms garner new venture capital backing, while VelaVigo and Conjustar were among the others bagging new funding for antibody- and peptide-drug conjugates.

funding
Venture capital and private equity firms helped create a much-needed uplift in China biotech financing over the past weeks. • Source: Shutterstock

More from Financing

More from Focus On Asia